A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open label, phase IV study conducted to evaluate the efficacy and
safety of agalsidase beta (Fabrazyme [recombinant form]) administered by intravenous drip
infusion in participants with cardiac Fabry disease.
Participants participated for 4 weeks or less in the baseline period and 156 weeks for the
treatment period.